|
KMID : 0614620080520060368
|
|
Korean Journal of Gastroenterology
2008 Volume.52 No. 6 p.368 ~ p.375
|
|
|
Clinical Outcomes of Lamivudine Therapy and HLA Alleles in Chronic Hepatitis B Patients
|
|
Oh Ji-Min
Kwon Kyu-Heum
Kim Jang-Eon
Choi Jin-Ho
Beom Sun-Hee
Lee Sang-Hyuk
Lee Yong-Jik
Park Mi-Young
Jung Mee-Kyung
Lee Kye-Heui
|
|
|
Abstract
|
|
|
Background/Aims: The human leukocyte antigen (HLA) system is an integral component of immune response.
Highly polymorphic HLA genes may play a pivotal role in the response of antiviral therapy. We investigated the effects of HLA gene polymorphism on the clinical outcome of chronic hepatitis B patients who received lamivudine treatment.
Methods: Depending on their clinical response to lamivudine therapy, a total of sixty one patients were divided into following groups; non-responders, viral breakthroughers, relapsers, and seroconverters. HLA-A, -B, -Cw, -DRB and HLA-DRB1 alleles typing was performed on each group through the polymerase chain reaction and the sequence-specific oligonucleotide hybridization method. The distribution patterns of HLA-A, HLA-B, HLA-Cw, HLA-DRB, and HLA-DRB1 were then analysed.
Results: When non-responders were compared to the other groups, high frequencies in HLA-Cw*1, HLA-DRB1*4 and HLA-DRB*4 (p=0.015, 0.033 and 0.004 respectively) were evident. When seroconverters were compared to viral breakthroughers, high frequencies in HLA-A*2 and HLA-DRB*4 (p=0.048, 0.025 respectively) were evident.
Conclusions: Our data suggests that HLA-A*2, HLA-Cw*1, HLA-DRB1*4 genes are related to the clinical outcomes of lamivudine treatment in chronic hepatitis B patients. These genes may be used in the prediction of the clinical outcome of lamivudine therapy in chronic hepatitis B patients.
|
|
|
KEYWORD
|
|
|
HLA, Hepatitis B virus (HBV), Lamivudine
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|
|